I21K (p.Ile21Lys) variant of KRAS (GTPase KRas)
I21K (p.Ile21Lys) in KRAS (GTPase KRas) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as uncertain significance in the context of Prostate cancer, hereditary, 1. The available variant effect predictions contribute to a CATVariant prioritization score of 0.61 / 1. The record also includes experimental measurements, published literature, and structural context.
I21K (p.Ile21Lys) variant details
- p.Ile21Lys
- rs2135805981
- ClinGen CA384157379
- ClinVar RCV002292311
- Uncertain significance
- Prostate cancer, hereditary, 1
- Missense
- Variant Prioritization Score for Impact Estimate 0.613
- AlphaMissense 1.00
- MetaLR 0.53
- MetaSVM 0.12
- PolyPhen-2 1.00
- SIFT 0.00
- EVE 0.72
- ClinVar: Uncertain significance (Prostate cancer, hereditary, 1)
- EBI: Variant of uncertain significance
- UniProt: Uncertain significance
- Structural context available
- abundance fitness from abundancePCA of KRAS block1: score 0.188
- Cited in: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic… (PMID 25394175)
- Cited in: Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. (PMID 31829902)